Eli Lilly's Mounjaro has overtaken Keytruda to become the world's top-selling medicine. Its rise highlights booming demand ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities ...

The NHS in East Yorkshire and North Lincolnshire is among the first in the UK to offer an injectable form of Keytruda, reducing treatment time from over an hour to just minutes. The change is expected ...

Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to ...

Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...

It's time to start thinking at least a little bit defensively by exchanging long-term potential gains for certain near-term ...

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s favorite stocks in the space. The shares are up by ...

Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges.

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...